Braveheart Bio opens at $30.20, IPO at $18

Braveheart Bio (BRVE), a clinical-stage biopharmaceutical company focused on developing therapies for hypertrophic cardiomyopathy and other cardiovascular diseases, saw its shares open at $30.20 on the Nasdaq Global Market on August 6, 2026, significantly above its IPO price of $18.00. The company raised $382.5 million from the offering of 21.25 million shares, with an additional 30-day option for underwriters to purchase up to 3.1875 million more shares. The IPO, which was upsized from an earlier planned offering of $318.8 million at a price range of $15 to $17 per share, reflects strong investor interest in the company’s lead product candidate, BHB-1893, an oral cardiac myosin inhibitor targeting both obstructive and non-obstructive forms of hypertrophic cardiomyopathy. The offering was managed by joint book-running managers Goldman Sachs, Jefferies, TD Cowen, Stifel, and Cantor. The company intends to use the proceeds for further development of BHB-1893, research and development, and general corporate purposes.